MS Center of the Shenandoah Valley

At Neurologic Associates treating patients with MS is our passion, striving to render this disease an inconvenience rather than a sentence of disability.
The treatment of MS has completely evolved in the last 12 years from a choice of 3 injectable medications that often left patients feeling ill more than 100 days a year to a once a month infused agent (Tysabri) that reduces new MRI lesions by 97%! More recently 3 oral agents Tecfidera, Gilenya and Aubagio have come to market. These agents reducing new MRI lesions by 20-30% over injectable agents. We are additionally pleased to order our patients Lemtrada and Ocrevus. -Lemtrada is an anti CD52 monoclonal antibody that specifically targets autoimmune T and B cells. Patients receive 5 days of infusion year 1, 3 days of infusion year 2. 50% of patients require no further treatment! Lemtrada reduces new MRI lesions by >95%
-Ocrevus is an anti CD20 monoclonal antibody that specifically targets autoimmune B cells. It is infused twice in 2 weeks to start, then twice a year thereafter. Ocrevus reduces new MRI lesions by >97%.
- Soliris is an anti C5 complement agent over 98% effective in preventing attacks of Neuromyelitis Optica (NMO). We have significant experience in infusing Solaris and can offer it to patients with NMO as well as ACH antibody positive Myasthenia Gravis.

In 2007 Neurologic Associates was the only center in the valley or in all of Northern Virginia administering Tysabri to patients with relapsing MS. Many of those patients are 9 years out without a single exacerbation.

If you’re still using injectable agents to treat your MS... we need to talk!

OUR MS CENTER IS DISTINGUISHED BY:

-Dr. Landrio and staffs vast experience in treating over 300 patients with relapsing MS

-Our in office infusion center caters to our patients schedule and comfort as compared with competitors that farm out infusion to an outside company with little scheduling flexibility.

-Our infusion nurse Sara Clem RN has extensive experience in hospital based infusion, and is our MS triage nurse and drug study coordinator.

-We draw our JC virus titers on site.

-Our philosophy of not “sitting back and watching” but rather treating MS aggressively. A single new lesion is one too many!

-We see our MS patients frequently and can see them urgently in the setting of an exacerbation. If IV steroids are required they are done that day onsite.